Does the Expression of Versican Isoforms Contribute to the Pathogenesis of Neurodegenerative Diseases?

Archives of Medical Research

Volumn 42, Issue 3, 2011, Pages 258-260

  Zhang, Zhen wei ^a   Zhang, Jian peng ^a   Zhou, Ting ting ^a   Feng, Wei hua ^a   Jiao, Bing hua ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Extracellular matrix; Neurodegenerative diseases; Versican isoforms

Indexed keywords

AMYLOID BETA PROTEIN; GLYCOSAMINOGLYCAN; ISOPROTEIN; PROTEOCHONDROITIN SULFATE; TAU PROTEIN; VERSICAN;

APOPTOSIS; ARTICLE; CANCER GROWTH; CATABOLISM; CELL ADHESION; CELL MATURATION; CELL PROLIFERATION; DEGENERATIVE DISEASE; EXTRACELLULAR MATRIX; HUMAN; NERVE CELL DIFFERENTIATION; NERVE CELL GROWTH; NERVE FIBER TRANSPORT; NERVE REGENERATION; PATHOGENESIS; PROTEIN EXPRESSION; SYNAPTIC TRANSMISSION;

ALTERNATIVE SPLICING; CHONDROITIN SULFATE PROTEOGLYCANS; HUMANS; NEOPLASMS; NEURODEGENERATIVE DISEASES; NEURONS; PROTEIN ISOFORMS; VERSICANS;

EID: 79959769137     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2011.04.010     Document Type: Article

References (28)

1. Bonneh-Barkay D., Wiley C.A. Brain extracellular matrix in neurodegeneration. Brain Pathol 2009, 19:573-585.
2. Viapiano M.S., Matthews R.T. From barriers to bridges: chondroitin sulfate proteoglycans in neuropathology. Trends Mol Med 2006, 12:487-496.
3. Gilbert R.J., McKeon R.J., Darr A., et al. CS-4,6 is differentially upregulated in glial scar and is a potent inhibitor of neurite extension. Mol Cell Neurosci 2005, 29:545-558.
4. Asher R.A., Morgenstern D.A., Moon L.D., et al. Chondroitin sulphate proteoglycans: inhibitory components of the glial scar. Prog Brain Res 2001, 132:611-619.
5. Kwok J.C., Afshari F., García-Alías G., et al. Proteoglycans in the central nervous system: plasticity, regeneration and their stimulation with chondroitinase ABC. Restor Neurol Neurosci 2008, 26:131-145.
6. Zako M., Shinomura T., Ujita M., et al. Expression of PG-M (V3), an alternatively spliced form of PG-M without a chondroitin sulfate attachment in region in mouse and human tissues. J Biol Chem 1995, 270:3914-3918.
7. Landolt R.M., Vaughan L., Winterhalter K.H., et al. Versican is selectively expressed in embryonic tissues that act as barriers to neural crest cell migration and axon outgrowth. Development 1995, 121:2303-2312.
8. Schmalfeldt M., Dours-Zimmermann M.T., Winterhalter K.H. Versican V2 is a major extracellular matrix component of the mature bovine brain. J Biol Chem 1998, 273:15758-15764.
9. Voutilainen K., Anttila M., Sillanpaa S., et al. Versican in epithelial ovarian cancer: relation to hyaluronan, clinicopathologic factors and prognosis. Int J Cancer 2003, 107:359-364.
10. Suwiwat S., Ricciardelli C., Tammi R., et al. Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res 2004, 10:2491-2498.
11. Ricciardelli C., Mayne K., Sykes P.J., et al. Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. Clin Cancer Res 1998, 4:963-971.
12. Pirinen R., Leinonen T., Böhm J., et al. Versican in nonsmall cell lung cancer: relation to hyaluronan, clinicopathologic factors, and prognosis. Human Pathol 2005, 36:44-50.
13. Kodama J., Hasengaowa, Kusumoto T., et al. Prognostic significance of stromal versican expression in human endometrial cancer. Ann Oncol 2007, 18:269-274.
14. Wu Y., Sheng W., Chen L., et al. Versican V1 isoform induces neuronal differentiation and promotes neurite outgrowth. Mol Biol Cell 2004, 15:2093-2104.
15. Schmalfeldt M., Bandtlow C.E., Dours-Zimmermann M.T., et al. Brain derived versican V2 is a potent inhibitor of axonal growth. J Cell Sci 2000, 113:807-816.
16. Sheng W., Wang G., Wang Y., et al. The roles of versican V1 and V2 isoforms in cell proliferation and apoptosis. Mol Biol Cell 2005, 16:1330-1340.
17. LaPierre D.P., Lee D.Y., Li S.Z., et al. The ability of versican to simultaneously cause apoptotic resistance and sensitivity. Cancer Res 2007, 67:4742-4750.
18. Kim S., Takahashi H., Lin W.W., et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009, 457:102-106.
19. DeWitt D.A., Silver J., Canning D.R., et al. Chondroitin sulfate proteoglycans are associated with the lesions of Alzheimer's disease. Exp Neurol 1993, 121:149-152.
20. Castillo G.M., Lukito W., Wight T.N., et al. The sulfate moieties of glycosaminoglycans are critical for the enhancement of β-amyloid protein fibril formation. J Neurochem 1999, 72:1681-1687.
21. McLaurin J., Franklin T., Zhang X.Q., et al. Interactions of Alzheimer amyloid-β peptides with glycosaminoglycans effects on fibril nucleation and growth. Eur J Biochem 1999, 266:1101-1110.
22. Cotman S.L., Halfter W., Cole G.J. Agrin binds to beta amyloid (Abeta), accelerates abeta fibril formation, and is localized to Abeta deposits in Alzheimer's disease brain. Mol Cell Neurosci 2000, 15:183-198.
23. van Horssen J., Wesseling P., van den Heuvel L.P., et al. Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders. Lancet Neurol 2003, 2:482-492.
24. DeWitt D.A., Richey P.L., Praprotnik D., et al. Chondroitin sulfate proteoglycans are a common component of neuronal inclusions and astrocytic reaction in neurodegenerative diseases. Brain Res 1994, 656:205-209.
25. Cohlberg J.A., Li J., Uversky V.N., et al. Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro. Biochemistry 2002, 41:1502-1511.
26. Wu Y., Sheng W., Dong H., et al. Versican isoforms modulate expression and function of nicotinic acetylcholine receptors. Int J Physiol Pathophysiol Pharmacol 2009, 1:64-75.
27. Dours-Zimmermann M.T., Maurer K., Rauch U., et al. Versican V2 assembles the extracellular matrix surrounding the nodes of ranvier in the CNS. J Neurosci 2009, 29:7731-7742.
28. Walker F.O. Huntington's disease. Lancet 2007, 369:218-228.